Evidence map›Paper›PMID 37670975›Full record

ReviewJournal of Cancer2023

Molecular Targets of Aptamers in Gastrointestinal Cancers: Cancer Detection, Therapeutic Applications, and Associated Mechanisms.

Khang Wen Goh, Annatasha Stephen, Yuan Seng Wu, Maw Shin Sim, Kalaivani Batumalaie, Subash C B Gopinath, Rhanye Mac Guad, Ashok Kumar, Mahendran Sekar, Vetriselvan Subramaniyan and 4 more

Open access · goldAbstract readReview
In one paragraph

Review in Journal of Cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Aptamers' Potential to Fill Therapeutic and Diagnostic Gaps.Pharmaceuticals (Basel, Switzerland) · 2024
    Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 11 institutions in 3 countries.

Khang Wen GohFaculty of Data Science and Information Technology, INTI International University, 71800 Nilai, Malaysia.
Annatasha StephenDepartment of Pharmaceutical Life Sciences, Faculty of Pharmacy, University of Malaya, Kuala Lumpur 50603, Malaysia.
Yuan Seng WuCentre for Virus and Vaccine Research, School of Medical and Life Sciences, Sunway University, Selangor 47500, Malaysia.
Maw Shin SimDepartment of Pharmaceutical Life Sciences, Faculty of Pharmacy, University of Malaya, Kuala Lumpur 50603, Malaysia.
Kalaivani BatumalaieDepartment of Biomedical Sciences, Faculty of Health Sciences, Asia Metropolitan University, 81750 Johor Bahru, Malaysia.
Subash C B GopinathFaculty of Chemical Engineering & Technology, Arau 02600, Institute of Nano Electronic Engineering, Kangar 01000, Micro System Technology, Centre of Excellence, Arau 02600, Pauh Campus, Universiti Malaysia Perlis (UniMAP), Perlis, Malaysia.
Rhanye Mac GuadDepartment of Biomedical Science and Therapeutics, Faculty of Medicine and Health Science, Universiti Malaysia Sabah, Kota Kinabalu, Sabah, Malaysia.
Ashok KumarDepartment of Internal Medicine, University of Kansas Medical Centre, Kansas City, Kansas 66103, United States.
Mahendran SekarSchool of Pharmacy, Monash University Malaysia, Bandar Sunway, Subang Jaya 47500, Malaysia.
Vetriselvan SubramaniyanDepartment of Pharmacology, Jeffrey Cheah School of Medicine and Health Sciences, MONASH University, Malaysia.
Neeraj Kumar FuloriaCentre of Excellence for Biomaterials Engineering & Faculty of Pharmacy, AIMST University, Bedong 08100, Malaysia.
Shivkanya FuloriaFaculty of Pharmacy, AIMST University, Semeling, Bedong 08100, Malaysia.
Appalaraju VelagaDepartment of Medicinal Chemistry, Faculty of Pharmacy, MAHSA University, Selangor 42610, Malaysia.
Md Moklesur Rahman SarkerDepartment of Pharmacy, State University of Bangladesh, 77 Satmasjid Road, Dhanmondi, Dhaka 1205, Bangladesh.
University of Malaya · MYAIMST University · MYDaffodil International University · BDINTI International University · MYMahsa University · MYMonash University Malaysia · MYNewcastle University Medicine Malaysia · MYSaveetha University · INState University of Bangladesh · BDSunway University · MYUniversiti of Malaysia Sabah · MY

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gastrointestinal (GI) cancers are among the most common cancers that impact the global population, with high mortality and low survival rates after breast and lung cancers. Identifying useful molecular targets in GI cancers are crucial for improving diagnosis, prognosis, and treatment outcomes, however, limited by poor targeting and drug delivery system. Aptamers are often utilized in the field of biomarkers identification, targeting, and as a drug/inhibitor delivery cargo. Their natural and chemically modifiable binding capability, high affinity, and specificity are favored over antibodies and potential early diagnostic imaging and drug delivery applications. Studies have demonstrated the use of different aptamers as drug delivery agents and early molecular diagnostic and detection probes for treating cancers. This review aims to first describe aptamers' generation, characteristics, and classifications, also providing insights into their recent applications in the diagnosis and medical imaging, prognosis, and anticancer drug delivery system of GI cancers. Besides, it mainly discussed the relevant molecular targets and associated molecular mechanisms involved, as well as their applications for potential treatments for GI cancers. In addition, the current applications of aptamers in a clinical setting to treat GI cancers are deciphered. In conclusion, aptamers are multifunctional molecules that could be effectively used as an anticancer agent or drug delivery system for treating GI cancers and deserve further investigations for clinical applications.

Indexed as

Alimentary and digestive tract cancercancer diagnosiscancer prognosisdrug deliverysingle-stranded oligonucleotidestherapeutic targets

Identifiers

PMID37670975
PMCPMC10475355
OpenAlexW4385711688

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.